Title
Proteinuria, Hypoalbuminemia, and Chronic Lymphocytic Leukemia: An Unusual Trio.

Permalink
https://escholarship.org/uc/item/5rj222x4

Authors
Wung, William
Ananthakrishnan, Shubha
Jonas, Brian A

Publication Date
2018

DOI
10.1177/2324709618764207

Peer reviewed
Proteinuria, Hypoalbuminemia, and Chronic Lymphocytic Leukemia: An Unusual Trio

William Wung, MD¹, Shubha Ananthakrishnan, MD¹, and Brian A. Jonas, MD¹

Abstract

Chronic lymphocytic leukemia (CLL) is a chronic, progressive lymphoproliferative disorder characterized by a monoclonal population of functionally incompetent lymphocytes. Renal involvement is rare and poorly described. A 57-year-old male with no prior medical history was diagnosed with CLL and followed with a watch and wait approach. He was referred to our institution several months later due to concern for Richter’s transformation to diffuse large B-cell lymphoma. A positron emission tomography/computed tomography scan showed no evidence of diffuse large B-cell lymphoma; however, the patient was noted to have hypoalbuminemia, nephrotic range proteinuria, an acute left renal vein thrombus, and a right pulmonary embolus. A nephrotic syndrome workup including autoimmunity and infection was unremarkable, and a kidney biopsy was deferred due to concern for renal compromise in the setting of a renal vein thrombus. The patient was treated with 6 cycles of reduced-dose fludarabine, cyclophosphamide, and rituximab for a presumed CLL-associated nephrotic syndrome and anticoagulation for his venous thromboemboli. At 6-month follow-up, the patient achieved complete remission of his CLL with normalization of all cell lines and resolution of his nephrotic range proteinuria. Repeat computed tomography scans showed no evidence of recurrent venous thromboemboli. This case demonstrates a potential role of empiric chemotherapy in cases of CLL-associated nephrotic syndrome given its potentially life-threatening sequelae and response to treatment.

Keywords

chronic lymphocytic leukemia, nephrotic syndrome, venous thromboemboli

Introduction

Chronic lymphocytic leukemia (CLL) is a progressive, lymphocytic disorder characterized by accumulation of immature, functionally incompetent lymphocytes. Staging is typically done via the Rai and Binet systems, both of which are based on the presence and degree of disease-related anemia, thrombocytopenia, and organomegaly (Tables 1 and 2). Treatment with chemoimmunotherapy or small molecular inhibitors is typically indicated for high-risk disease (eg, Binet stage C or Rai stage III/IV) and select cases of intermediate disease (Binet stage B or Rai stage I/II). Renal involvement such as nephrotic syndrome is rare and poorly described. We present a case of a 56-year-old male with CLL who presented with nephrotic range proteinuria and venous thromboemboli, both of which subsequently resolved with treatment of his CLL.

Case Report

A 57-year-old male with no prior medical history presented to an outside hospital with progressive fatigue, decreased exercise tolerance, and lower extremity edema of 3 months duration.

¹University of California, Davis, Sacramento, CA, USA

Received November 16, 2017. Revised February 9, 2018. Accepted February 17, 2018.

Corresponding Author:
Brian A. Jonas, Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, Suite 3016, 4501 X Street, Sacramento, CA 95817, USA.
Email: bajonas@ucdavis.edu

No lymphadenopathy or hepatosplenomegaly was noted on exam. Laboratory tests were significant for a leukocytosis of 95 200/µL with 84% lymphocytes, smudge cells on peripheral smear, hemoglobin 13.2 g/dL, platelet count 177 000/µL, creatinine 1.2 mg/dL, serum albumin 2.1 g/dL, and hemoglobin A1c of 5.7% (Table 3). No prior laboratory tests were available for comparison, as the patient had not seen a physician in several years. Peripheral blood immunophenotyping showed a monoclonal population of cells positive for CD5, CD19, CD20, CD22, and CD23 and negative for CD38, an immunophenotype that is consistent with CLL. Peripheral blood fluorescent in situ hybridization was positive for trisomy 12 and negative for del(11p), del(13q), and del(17q). ZAP70 and immunoglobulin heavy-chain variable-region

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
mutations were also negative. Serum β-2 microglobulin was elevated at 3.7 µg/mL (normal 0-3 µg/mL). The patient was diagnosed with Rai stage 0 CLL and was followed with a watch and wait approach until approximately 6 months afterward when a computed tomography (CT) scan reportedly showed a left lower quadrant mass concerning for possible Richter’s transformation to diffuse large B-cell lymphoma. He was subsequently referred to our institution for further evaluation.

On admission, physical exam was significant for bilateral axillary and inguinal lymphadenopathy, hepatomegaly, splenomegaly, and diffuse anasarca with pronounced scrotal edema. Laboratory tests were notable for a leukocytosis 77 000/µL with 93% lymphocytes, hemoglobin 11.5 g/dL, platelet count 174 000/µL, creatinine 1.3 mg/dL, estimated creatinine clearance (CrCl) of 95 mL/min, and serum albumin 1.4 g/dL (Table 3). Platelets, serum electrolytes, transaminases, alkaline phosphatase, total bilirubin, and international normalized ratio were within normal limits. Repeat peripheral blood flow cytometry confirmed CLL with normalization of all cell lines, serum creatinine, hypoalbuminemia, and nephrotic range proteinuria (Table 3). No lymphadenopathy was noted, and repeat CT scans showed no evidence of recurrent venous thromboemboli.

### Discussion

Kidney involvement is an uncommon but potentially serious sequela of CLL, can occur at any stage of CLL, and should be considered as a leading diagnosis once other causes of renal impairment have been considered. Membranoproliferative glomerulonephritis (MPGN) is the most common cause of CLL-associated renal involvement, with CLL-cell infiltration, thrombotic microangiopathy (TMA), and minimal change disease as other notable etiologies. Cases of CLL-associated focal segmental glomerulosclerosis have been reported as well.

Evaluation involves a thorough history and physical exam, urinalyses, and serologies to evaluate for other causes of nephrotic and/or nephritic syndromes, for example, autoimmunity, infection, and so on. Anti-phospholipase A2 receptor antibodies are often used in evaluation of idiopathic membranous nephropathy; however, their role in CLL-associated renal impairment is less well established. Diagnosis often ultimately entails a renal biopsy in order to differentiate among the different etiologies of kidney damage. This is especially important given the differences in management and prognosis. For instance, several cases of renal TMA diagnosed on biopsy resolved after discontinuation of chemotherapy, in particular pentostatin, that itself has been associated with TMA. Conversely, CLL-associated MPGN
appears to respond well to alkylating agents, in particular cyclophosphamide, especially given their existing use in treating idiopathic MPGN.4

It is unclear if any specific CLL stage, mutation, or serologic marker predisposes to a higher or lower risk of CLL-associated kidney injury. The Rai and Binet staging systems are typically used to determine prognosis and/or decision to initiate treatment. However, these are based on physical exam and complete blood count, and do not include existing or future risk of kidney function impairment. Trisomy 12 and del(13q) have been associated with favorable prognoses (eg, progression-free survival, response to treatment, etc), while del(11q), del(17q), CD38, immunoglobulin heavy chain variable region gene mutations, and elevated β-2 microglobulin levels have been associated with poor prognoses.5 However, a single-center case series of 49 patients with biopsy-proven CLL-associated renal injury including nephrotic syndrome showed no predominant mutations, immunophenotypes, or serologic markers.4 Another multicenter case series of 15 similar patients was also inconclusive.8 Further work such as a systematic review with a larger sample size may elucidate further insight into potential genetic and/or serologic risk factors of CLL-associated renal injury.

Kidney involvement also has potential implications toward CLL treatment. Currently, there is no standard regimen and/or agent(s) for treatment of symptomatic CLL. Specific agents include purine analogs (eg, fludarabine, pentostatin), alkylating agents (eg, chlorambucil, cyclophosphamide, bendamustine), monoclonal antibodies (eg, rituximab), and Bruton’s tyrosine kinase inhibitors (eg, ibrutinib). Most young (<70 years), previously untreated patients with intact
renal function are treated with fludarabine-based therapy including cyclophosphamide and/or rituximab (FCR and FR, respectively), as these regimens have demonstrated superior response rates and progress-free survival in this patient population when compared with other regimens (eg, chlorambucil-based). However, CrCl is one of the strongest predictors of fludarabine toxicity, as such non-fludarabine regimens are often chosen in patients with an estimated CrCl <80 mL/min. Bendamustine plus rituximab appears to be slightly less effective but with similar overall survival rates and less toxic effects when compared with FCR. Chlorambucil is also sometimes used for cases of CLL with renal impairment, but this has shown to be inferior to fludarabine- and bendamustine-based regimens.

In the case of our patient, his profound anasarca, hypoalbuminemia, proteinuria, venous thromboemboli, normal transaminases, and international normalized ratio were suggestive of an underlying nephrotic syndrome. However, his workup for autoimmunity, infection, and other common causes of nephrotic range proteinuria was unrevealing. Therefore, we attributed his nephrotic syndrome to his known CLL as a diagnosis of exclusion. We discussed a potential kidney biopsy with multiple consulting teams to further elucidate the mechanism of kidney injury. However, this was deferred given that (1) his left kidney was already compromised by his left renal vein thrombus and (2) risk of acute renal failure if his right kidney were to be injured during said biopsy. Therefore, we decided to initiate chemoinmunotherapy despite our patient having Rai stage II CLL given that there were no other explainable causes of nephrotic syndrome. We chose FCR because of its superiority over non-fludarabine regimens in young, previously untreated patients such as ours, and because his CrCl was well over 80 mL/min at time of chemotherapy initiation. Although current guidelines do not include CLL-associated nephrotic syndrome as an indication for treatment, we felt the benefits outweighed the risk in this situation especially given his multiple complications.

Our case shows that CLL can cause nephrotic syndrome in the absence of other etiologies. We also demonstrate that a renal biopsy, although helpful, may not always be needed in such cases. Our case also shows that CLL-associated nephrotic syndrome may be an indication for CLL treatment when no other indications exist, in particular with FCR chemoinmunotherapy in cases without severe renal impairment. To our knowledge, this is the only reported case of CLL-associated nephrotic syndrome that resolved with FCR. It is unknown if newer agents (eg, ibrutinib, idelaisib, venoctxl) or monoclonal antibodies would have the same effect.

Authors’ Note

WW, SA, and BAJ collected and reviewed patient data. WW and BAJ analyzed and interpreted the data. WW, SA, and BAJ wrote and edited the manuscript. All authors agree on the final manuscript.

Acknowledgment

The authors would like to thank Dr Amina Naqvi of Mercy Oncology in Redding, CA, for contributing patient data.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: BAJ is supported by the National Cancer Institute of the National Institutes of Health under Award Number K12CA138464. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Ethics Approval

Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent

Verbal informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

References

1. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446-460. doi:10.1002/ajh.23979.
2. Seney FD Jr, Federgreen WR, Stein H, Kashgarian M. A review of nephrotic syndrome associated with chronic lymphocytic leukemia. Arch Intern Med. 1986;146:137-141.
3. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498-503. doi:10.1200/jco.2008.17.2619.
4. Stratil P, Nasr SH, Leung N, et al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica. 2015;100:1180-1188.
5. Rosado MF, Morgensztern D, Abdullah S, Ruiz P, Lossos IS. Chronic lymphocytic leukemia-associated nephrotic syndrome caused by focal segmental glomerulosclerosis. Am J Hematol. 2004;77:205-206.
6. Dai H, Zhang H, He Y. Diagnostic accuracy of PL2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep. 2015;5:8803.
7. Yahata N, Kawanishi Y, Okabe S, et al. Membranous glomerulonephritis with nephrotic syndrome associated with chronic lymphocytic leukemia. Am J Nephrol. 2000;20:402-407.
8. Poitou-Verkinder AL, Francois A, Drieux F, et al. The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma: a 25-year multicenter experience. PLoS One. 2015;10:e0119156. doi:10.1371/journal.pone.0119156.
9. Martell ME, Peterson BL, Cohen HJ, et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. *Cancer Chemother Pharmacol*. 2002;50:37-45. doi:10.1007/s00280-002-0443-5.

10. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemioimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. *Lancet Oncol*. 2016;17;928-942. doi:10.1016/S1470-2045(16)30051-1.

11. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bundamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. *Br J Haematol*. 2012;159:67-77. doi:10.1111/bjh.12000.